Financhill
Buy
59

AKRO Quote, Financials, Valuation and Earnings

Last price:
$51.82
Seasonality move :
-12.73%
Day range:
$51.09 - $52.74
52-week range:
$17.86 - $58.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.90x
Volume:
816.6K
Avg. volume:
1.8M
1-year change:
115.43%
Market cap:
$3.6B
Revenue:
--
EPS (TTM):
-$3.78

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AKRO
Akero Therapeutics
-- -$1.12 -- -10.94% $78.27
ALLK
Allakos
-- -$0.18 -- -71.72% $0.35
BIIB
Biogen
$2.4B $3.36 -1.62% 35.61% $201.38
CYTK
Cytokinetics
$14.3M -$1.17 523.13% -2.44% $79.55
ETNB
89bio
-- -$0.76 -- -19.32% $30.67
SAGE
Sage Therapeutics
$14.4M -$1.36 79.76% -43.33% $8.23
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AKRO
Akero Therapeutics
$51.79 $78.27 $3.6B -- $0.00 0% --
ALLK
Allakos
$0.29 $0.35 $25.5M -- $0.00 0% --
BIIB
Biogen
$140.64 $201.38 $20.6B 12.57x $0.00 0% 2.12x
CYTK
Cytokinetics
$50.26 $79.55 $5.9B -- $0.00 0% 1,670.44x
ETNB
89bio
$11.06 $30.67 $1.6B -- $0.00 0% --
SAGE
Sage Therapeutics
$7.31 $8.23 $449.4M -- $0.00 0% 10.77x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AKRO
Akero Therapeutics
-- 3.272 -- --
ALLK
Allakos
-- -2.969 -- --
BIIB
Biogen
27.36% 0.011 28.25% 0.77x
CYTK
Cytokinetics
102.17% 0.539 10.54% 9.22x
ETNB
89bio
-- 2.921 -- --
SAGE
Sage Therapeutics
-- 0.458 -- 7.17x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AKRO
Akero Therapeutics
-- -$81.7M -- -- -- -$70.4M
ALLK
Allakos
-- -$19.8M -- -- -- -$31.7M
BIIB
Biogen
$1.9B $450.6M 7.33% 10.33% 14.32% $694.6M
CYTK
Cytokinetics
-$84.1M -$140.8M -142.05% -- -29858.96% -$102.2M
ETNB
89bio
-- -$151.9M -- -- -- -$145.4M
SAGE
Sage Therapeutics
$11.3M -$80.3M -63.59% -63.59% -626.87% -$66.6M

Akero Therapeutics vs. Competitors

  • Which has Higher Returns AKRO or ALLK?

    Allakos has a net margin of -- compared to Akero Therapeutics's net margin of --. Akero Therapeutics's return on equity of -- beat Allakos's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$1.05 --
    ALLK
    Allakos
    -- -$0.21 --
  • What do Analysts Say About AKRO or ALLK?

    Akero Therapeutics has a consensus price target of $78.27, signalling upside risk potential of 51.14%. On the other hand Allakos has an analysts' consensus of $0.35 which suggests that it could grow by 22.51%. Given that Akero Therapeutics has higher upside potential than Allakos, analysts believe Akero Therapeutics is more attractive than Allakos.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    8 0 0
    ALLK
    Allakos
    0 7 0
  • Is AKRO or ALLK More Risky?

    Akero Therapeutics has a beta of -0.106, which suggesting that the stock is 110.555% less volatile than S&P 500. In comparison Allakos has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.406%.

  • Which is a Better Dividend Stock AKRO or ALLK?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Allakos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Allakos pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or ALLK?

    Akero Therapeutics quarterly revenues are --, which are smaller than Allakos quarterly revenues of --. Akero Therapeutics's net income of -$72.7M is lower than Allakos's net income of -$18.4M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Allakos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus -- for Allakos. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$72.7M
    ALLK
    Allakos
    -- -- -- -$18.4M
  • Which has Higher Returns AKRO or BIIB?

    Biogen has a net margin of -- compared to Akero Therapeutics's net margin of 10.87%. Akero Therapeutics's return on equity of -- beat Biogen's return on equity of 10.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$1.05 --
    BIIB
    Biogen
    76.23% $1.83 $23B
  • What do Analysts Say About AKRO or BIIB?

    Akero Therapeutics has a consensus price target of $78.27, signalling upside risk potential of 51.14%. On the other hand Biogen has an analysts' consensus of $201.38 which suggests that it could grow by 43.19%. Given that Akero Therapeutics has higher upside potential than Biogen, analysts believe Akero Therapeutics is more attractive than Biogen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    8 0 0
    BIIB
    Biogen
    13 17 0
  • Is AKRO or BIIB More Risky?

    Akero Therapeutics has a beta of -0.106, which suggesting that the stock is 110.555% less volatile than S&P 500. In comparison Biogen has a beta of -0.082, suggesting its less volatile than the S&P 500 by 108.236%.

  • Which is a Better Dividend Stock AKRO or BIIB?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or BIIB?

    Akero Therapeutics quarterly revenues are --, which are smaller than Biogen quarterly revenues of $2.5B. Akero Therapeutics's net income of -$72.7M is lower than Biogen's net income of $266.7M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 12.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 2.12x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$72.7M
    BIIB
    Biogen
    2.12x 12.57x $2.5B $266.7M
  • Which has Higher Returns AKRO or CYTK?

    Cytokinetics has a net margin of -- compared to Akero Therapeutics's net margin of -34674.95%. Akero Therapeutics's return on equity of -- beat Cytokinetics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$1.05 --
    CYTK
    Cytokinetics
    -18174.73% -$1.36 $642.1M
  • What do Analysts Say About AKRO or CYTK?

    Akero Therapeutics has a consensus price target of $78.27, signalling upside risk potential of 51.14%. On the other hand Cytokinetics has an analysts' consensus of $79.55 which suggests that it could grow by 58.28%. Given that Cytokinetics has higher upside potential than Akero Therapeutics, analysts believe Cytokinetics is more attractive than Akero Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    8 0 0
    CYTK
    Cytokinetics
    10 3 0
  • Is AKRO or CYTK More Risky?

    Akero Therapeutics has a beta of -0.106, which suggesting that the stock is 110.555% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.827, suggesting its less volatile than the S&P 500 by 17.271%.

  • Which is a Better Dividend Stock AKRO or CYTK?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or CYTK?

    Akero Therapeutics quarterly revenues are --, which are smaller than Cytokinetics quarterly revenues of $463K. Akero Therapeutics's net income of -$72.7M is higher than Cytokinetics's net income of -$160.5M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 1,670.44x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$72.7M
    CYTK
    Cytokinetics
    1,670.44x -- $463K -$160.5M
  • Which has Higher Returns AKRO or ETNB?

    89bio has a net margin of -- compared to Akero Therapeutics's net margin of --. Akero Therapeutics's return on equity of -- beat 89bio's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$1.05 --
    ETNB
    89bio
    -- -$1.39 --
  • What do Analysts Say About AKRO or ETNB?

    Akero Therapeutics has a consensus price target of $78.27, signalling upside risk potential of 51.14%. On the other hand 89bio has an analysts' consensus of $30.67 which suggests that it could grow by 177.28%. Given that 89bio has higher upside potential than Akero Therapeutics, analysts believe 89bio is more attractive than Akero Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    8 0 0
    ETNB
    89bio
    7 1 0
  • Is AKRO or ETNB More Risky?

    Akero Therapeutics has a beta of -0.106, which suggesting that the stock is 110.555% less volatile than S&P 500. In comparison 89bio has a beta of 1.076, suggesting its more volatile than the S&P 500 by 7.625%.

  • Which is a Better Dividend Stock AKRO or ETNB?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 89bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. 89bio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or ETNB?

    Akero Therapeutics quarterly revenues are --, which are smaller than 89bio quarterly revenues of --. Akero Therapeutics's net income of -$72.7M is higher than 89bio's net income of -$149.1M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while 89bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus -- for 89bio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$72.7M
    ETNB
    89bio
    -- -- -- -$149.1M
  • Which has Higher Returns AKRO or SAGE?

    Sage Therapeutics has a net margin of -- compared to Akero Therapeutics's net margin of -747.33%. Akero Therapeutics's return on equity of -- beat Sage Therapeutics's return on equity of -63.59%.

    Company Gross Margin Earnings Per Share Invested Capital
    AKRO
    Akero Therapeutics
    -- -$1.05 --
    SAGE
    Sage Therapeutics
    88.38% -$1.56 $465.1M
  • What do Analysts Say About AKRO or SAGE?

    Akero Therapeutics has a consensus price target of $78.27, signalling upside risk potential of 51.14%. On the other hand Sage Therapeutics has an analysts' consensus of $8.23 which suggests that it could grow by 12.52%. Given that Akero Therapeutics has higher upside potential than Sage Therapeutics, analysts believe Akero Therapeutics is more attractive than Sage Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    AKRO
    Akero Therapeutics
    8 0 0
    SAGE
    Sage Therapeutics
    0 15 0
  • Is AKRO or SAGE More Risky?

    Akero Therapeutics has a beta of -0.106, which suggesting that the stock is 110.555% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.234%.

  • Which is a Better Dividend Stock AKRO or SAGE?

    Akero Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akero Therapeutics pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AKRO or SAGE?

    Akero Therapeutics quarterly revenues are --, which are smaller than Sage Therapeutics quarterly revenues of $12.8M. Akero Therapeutics's net income of -$72.7M is higher than Sage Therapeutics's net income of -$95.8M. Notably, Akero Therapeutics's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akero Therapeutics is -- versus 10.77x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AKRO
    Akero Therapeutics
    -- -- -- -$72.7M
    SAGE
    Sage Therapeutics
    10.77x -- $12.8M -$95.8M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Walmart Stock Fall?
Why Did Walmart Stock Fall?

Walmart (NYSE:WMT) tumbled in spite of strong Q4 results that…

Is Cadence Stock a Buy, Sell or Hold?
Is Cadence Stock a Buy, Sell or Hold?

Cadence Design Systems (NASDAQ:CDNS) has seen its stock move sharply…

Is PFE the Best Dividend Play in Its Industry?
Is PFE the Best Dividend Play in Its Industry?

By their inherent nature, established pharma companies face a demand…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Sell
2
GLOB alert for Feb 22

Globant SA [GLOB] is down 27.81% over the past day.

Sell
42
CELH alert for Feb 22

Celsius Holdings [CELH] is up 27.77% over the past day.

Buy
60
HIMS alert for Feb 22

Hims & Hers Health [HIMS] is down 25.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock